Retevmo is a new FDA-approved oral targeted therapy
What is Retevmo?
Retevmo is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non-small cell lung cancer (NSCLC) that has spread, adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy), and adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that Retevmo is right for you. It is not known if Retevmo is safe and effective in children younger than 12 years of age.
Retevmo was approved based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long the response lasted. Studies are ongoing to confirm the benefit of Retevmo for this use.
Retevmo may affect both healthy cells and tumor cells, which can result in side effects, some of which can be serious.
Retevmo is a targeted cancer therapy; it is not chemotherapy.